Patent · US Active

Host cell kinases as targets for antiviral therapies against HCV infection

US8759010B2 · kind B2 · utility

0Cited by

0References

4Claims

0Family size

Assignee

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR

Inventors

Thomas Baumert · Glückstadt, DE
Joachim Lupberger · Strasbourg, FR

Key dates

Filing date	Sep 18, 2009
Grant date	Jun 24, 2014
Priority date	—
Expiry date	Dec 8, 2029

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/186
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention provides several networks of cellular protein kinases as potential targets for medical intervention against hepatitis C virus (HCV) infection and HCV-related diseases and disorders in mammals, including humans. The invention relates to therapeutic protocols and pharmaceutical compositions designed to inhibit the activity of one or more of these protein kinases for the prevention and/or treatment of infections and diseases caused by HCV. The invention also relates to methods for the identification of kinase inhibitors that may be used to treat and/or prevent HCV infections and HCV-related diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.